Richard Lehman reviews the latest research in the leading medical journals. […]
Richard Lehman’s weekly review of medical journals
Richard Lehman’s journal review—27 February 2017
NEJM 23 Feb 2017 Vol 376 Kallikrein rises from the footnotes The curious word “kallikrein” first appeared in 1934, when Eugen Werle discovered an inflammatory chemical in plasma which he […]
Richard Lehman’s journal review—20 February 2017
NEJM 16 Feb 2017 Vol 376 Periviable infant outcomes “Periviable” is a new word to me. I think I shall start using it for pieces of cheese that have been […]
Richard Lehman’s journal review—13 February 2017
NEJM 9 Feb 2017 Vol 376 Middle East Respiratory Syndrome Remember MERS? It was the talk of the town five years ago when it was first identified in Saudi Arabia. […]
Richard Lehman’s journal review—6 February 2017
NEJM 2 Feb 2017 Vol 376 Adding bicalutamide to RT for recurrent prostate cancer So far, this year is proving a good one for urology studies. Here are the follow-up […]
Richard Lehman’s journal review—30 January 2017
NEJM 26 Jan 2017 Vol 376 Bezlotoxumab Bezlotoxumab is an antibody that offers passive protection against Clostridium difficile toxin. This trial shows that if you give it with anti-clostridial antibiotics, […]
Richard Lehman’s journal review—23 January 2017
NEJM 19 Jan 2017 Vol 376 Transmission of drug resistant TB Tuberculosis in Europe used to be known as the White Death, and that is the title of the best […]
Richard Lehman’s journal review—16 January 2017
NEJM 12 Jan 2017 Vol 376 PROMS and PROs I first went to the Proms in 1966. I enjoyed the queuing, the atmosphere, and the music: young Barenboim playing Beethoven […]
Richard Lehman’s journal review—9 January 2017
NEJM 5 Jan 2017 Vol 376 The trials of big pharma As a fan of Ben Goldacre’s Bad Pharma and Peter Gøtzsche’s Deadly Medicines and Organised Crime, I was not […]
Richard Lehman’s journal review—3 January 2017
NEJM 22-29 Dec 2016 Vol 375 Co-amoxiclav for OM in under-twos This trial firmly establishes the superiority of a ten day over a five day course of co-amoxiclav for babies […]